

## **UC Irvine**

### **Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health**

#### **Title**

Update on Neurological Manifestations of SARS-CoV-2

#### **Permalink**

<https://escholarship.org/uc/item/06b4d8fk>

#### **Journal**

Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health, 21(6)

#### **ISSN**

1936-900X

#### **Authors**

Valiuddin, Hisham M.  
Kalajdzic, Almir  
Rosati, James  
et al.

#### **Publication Date**

2020

#### **DOI**

10.5811/westjem.2020.8.48839

#### **Copyright Information**

Copyright 2020 by the author(s). This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

# Update on Neurological Manifestations of SARS-CoV-2

Hisham M. Valiuddin, DO\*  
 Almir Kalajdzic, DO†  
 James Rosati, DO†  
 Kevin Boehm, DO‡  
 Dominique Hill, MD†

\*University of Pennsylvania, Department of Emergency Medicine, Philadelphia, Pennsylvania

†St. Mary Mercy Hospital, Department of Emergency Medicine, Livonia, Michigan

‡Broward Health Medical Center, Department of Emergency Medicine, Fort Lauderdale, Florida

Section Editor: Richard Lucarelli, MD

Submission history: Submitted June 21, 2020; Revision received August 2, 2020; Accepted August 10, 2020

Electronically published October 6, 2020

Full text available through open access at [http://escholarship.org/uc/uciem\\_westjem](http://escholarship.org/uc/uciem_westjem)

DOI: 10.5811/westjem.2020.8.48839

Severe acute respiratory syndrome coronavirus 2, the source of COVID-19, causes numerous clinical findings including respiratory and gastrointestinal findings. Evidence is now growing for increasing neurological symptoms. This is thought to be from direct in-situ effects in the olfactory bulb caused by the virus. Angiotensin-converting enzyme 2 receptors likely serve as a key receptor for cell entry for most coronaviridae as they are present in multiple organ tissues in the body, notably neurons, and in type 2 alveolar cells in the lung. Hematogenous spread to the nervous system has been described, with viral transmission along neuronal synapses in a retrograde fashion. The penetration of the virus to the central nervous system (CNS) allows for the resulting intracranial cytokine storm, which can result in a myriad of CNS complications. There have been reported cases of associated cerebrovascular accidents with large vessel occlusions, cerebral venous sinus thrombosis, posterior reversible encephalopathy syndrome, meningoencephalitis, acute necrotizing encephalopathy, epilepsy, and myasthenia gravis. Peripheral nervous system effects such as hyposmia, hypogeusia, ophthalmoparesis, Guillain-Barré syndrome, and motor peripheral neuropathy have also been reported. In this review, we update the clinical manifestations of COVID-19 concentrating on the neurological associations that have been described, including broad ranges in both central and peripheral nervous systems. [West J Emerg Med. 2020;21(6)45-51.]

*Disclaimer: Due to the rapidly evolving nature of this outbreak, and in the interests of rapid dissemination of reliable, actionable information, this paper went through expedited peer review. Additionally, information should be considered current only at the time of publication and may evolve as the science develops.*

## INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the source of coronavirus disease 2019 (COVID-19), causes numerous clinical findings including well described respiratory and gastrointestinal findings. While literature on SARS-CoV-2 association with neurological findings was initially sparse, evidence is now rapidly growing for this potentially devastating link. Vigilance is important to recognize all possible sequelae of COVID-19; additionally, early detection and recognition is a mainstay of medicine across any disease.

During the initial outbreak in Wuhan, China, a wide range of clinical presentations was found beyond the typical respiratory symptoms, with close to 50% of patients having gastrointestinal (GI) symptoms, and 7% of patients having no respiratory symptoms.<sup>1</sup> While the US Centers for Disease Control and Prevention (CDC) definition of persons under investigation for COVID-19 has evolved, it generally includes the presence of fever and signs and symptoms of respiratory illness. While this may encompass a large number of cases, it also leaves a big gap in untested patients with minimal to no respiratory symptoms including those with only GI or neurologic symptoms. Earliest reports from Wuhan found that over 36% of patients had some degree of nervous system involvement, the most common being dysfunction of the central nervous system (CNS) with close to 15% of patients having complaints of dizziness or headache.<sup>2</sup> In this article we provide a review of central and peripheral nervous system (PNS) involvement of SARS-CoV-2 (Table 1).

## METHODS

We conducted a literature review to obtain data regarding neurologic manifestations of COVID-19. All searches were done in May 2020 using Google searches, Google Scholar, and PubMed using combinations of the following keywords: “COVID,” “CNS,” “PNS,” “neurologic,” “coronavirus,” “manifestation,” “symptoms,” and “nervous.” Articles were initially selected based on their titles and abstracts for relevance to our review. Table 1 shows the case reports, reviews, and studies that were included in our review. We included articles that described central or peripheral nervous system neurological sequelae in patients with COVID-19. Articles were published between November 2019–May 2020. Exclusion criteria consisted of any articles that did not describe neurologic involvement of COVID-19. In total we included 26 articles in our review, which consisted of case reports and case series, as well as retrospective and prospective observational studies. We excluded 307 articles as not being pertinent to the neurological scope of this study. Also included in our review are articles that discuss potential mechanisms of neurologic involvement of COVID-19 to provide a better understanding of the disease process being described.

## DISCUSSION

SARS-CoV-1 from the early 2000s was found to have neurologic spread, with evidence of the virus isolated from cerebral spinal fluid (CSF) fluid.<sup>3</sup> The route of entry to the brain appeared to be predominantly through olfactory bulb neurons.<sup>3</sup> The intense systemic inflammatory response associated with viral infection can lead to blood-brain barrier breakdown, allowing cytokines access to the CNS.<sup>4,5,6</sup> The penetration of the virus to the CNS allows for the resulting intracranial cytokine storm, which can result in complications such as acute necrotizing encephalopathy (ANE), CNS disturbances, headache, trouble walking, visual disturbances, weakness, and even stroke.<sup>7,8</sup> This cytokine response can cause a myriad of hematologic issues ranging from thrombosis to a hemophagocytic lymphohistiocytosis.<sup>9</sup>

Transmission of the SARS-CoV-2 virus can occur via droplet and contact transmission as well as through airborne route under specific circumstances.<sup>10,11</sup> SARS-CoV-2 can enter the CNS through the cribriform plate and cause neurologic symptoms.<sup>5,6</sup> Initially, a group from France looked at the utility of using hyposmia and hypogeusia as a screening tool for COVID testing, and found that close to 20% of patients who tested positive for SARS-CoV2 had self-reported hyposmia and hypogeusia.<sup>12</sup> This is thought to be from direct in-situ effects in the olfactory bulb caused by the virus. Due to the reported frequency of hyposmia and hypogeusia, the American Academy of Otolaryngology Head and Neck Surgery and the British Association of Otorhinolaryngology now recommend that these symptoms be added to the list of primary screening symptoms for COVID-19. However, this is not a finding that

### *Population Health Research Capsule*

What do we already know about this issue?  
*COVID-19 can severely affect many organ systems, including respiratory, gastrointestinal, and nervous.*

What was the research question?  
*What are the current known neurological manifestations of the SARS-CoV-2 virus?*

What was the major finding of the study?  
*Broad and diverse nervous system involvement, including central and peripheral nervous systems, have been identified.*

How does this improve population health?  
*This review provides an increased awareness of the signs, symptoms, and presentations of neurological complications associated with COVID-19.*

is unique to SARS-CoV-2, as many respiratory viruses have been associated with hyposmia and hypogeusia in the past.

In addition to the novel SARS-CoV2, other coronaviridae, enteroviridae, rhinoviridae, parainfluenza virus, and Epstein-Barr virus have all been associated with post viral olfactory dysfunction (PVOD).<sup>13</sup> While the percentage of patients with a viral illness who develop olfactory dysfunction is unclear, the phenomenon is well described in the literature. Quint and colleagues looked at a series of 120 patients who had nonconductive olfactory disorders and found upper respiratory infection (URI) to be the most common cause, occurring in 42.5% of the patients.<sup>14</sup> The olfactory dysfunction occurs in the acute symptomatic phase of the virus and then often persists for a prolonged period of time thereafter.<sup>14</sup> The initial dysfunction could be attributed to mucosal edema, but in many cases the olfactory dysfunction persists.

When explored further, varying pathologies were identified. Douek and colleagues identified extensive scarring on biopsy as well as replacement of the olfactory epithelium with respiratory epithelium in patients with PVOD.<sup>15</sup> Additionally, Jafek and colleagues found decreased numbers of olfactory receptors in patients with PVOD.<sup>16</sup> Yamagishi and colleagues also identified decreased numbers of olfactory receptors and nerve bundles in post-URI olfactory loss.<sup>17, 18, 19</sup> Early reports from Wuhan found that approximately 5% of patients had impairment of taste and smell, while later reports from Vaira et al demonstrate a much higher

incidence, upwards of 19% of the 324 patients evaluated.<sup>20</sup> Additionally, the reports out of Wuhan revealed 13% of patients had headaches, and in severe disease they noted acute cerebrovascular accident (CVA) presented in close to 6% of patients in the intensive care unit (ICU).<sup>1</sup> Central and peripheral nervous system involvement has been described through a variety of presentations.

## Peripheral Nervous System

### *Guillain-Barré Syndrome*

PNS findings include hyposmia and hypogeusia as discussed above, and there have been cases reported of Guillain-Barré syndrome (GBS). One case report described a confirmed COVID-19 patient who developed progressive bilateral ascending paralysis two weeks after developing respiratory symptoms.<sup>21</sup> This patient had electromyography and neuronal testing that was consistent with GBS and was treated with intravenous immunoglobulin (IVIG) 0.40 grams per kilogram per day; however, the patient refused lumbar puncture for CSF analysis. No outcome post treatment was reported.

A case series of five COVID-19 patients with new diagnosis of GBS in Northern Italy did report post-IVIG outcome measures.<sup>22</sup> All five of the patients were found to have CSF testing that showed less than five white blood cells per cubic millimeter, and negative reverse transcription polymerase chain reaction assay for SARS-CoV-2.<sup>22</sup> All of these patients underwent IVIG treatment, two of whom received a second course of IVIG and a third who received plasma exchange.<sup>22</sup> The outcomes reported that of the two patients who received a second course of IVIG, one remained in the ICU on mechanical ventilation at four weeks post-IVIG, while the other had bulbar symptom improvement although minimal improvement in extremity weakness. The patient who received plasmapheresis remained tetraplegic and ventilator dependent four weeks post treatment. Of the two patients who received only one course of IVIG, one who presented initially with only mild facial and upper extremity weakness had improvement of symptom and discharge; the other patient who presented with moderate to severe upper and lower extremity weakness was still unable to stand and was transferred to a rehabilitation center.

### *Bell's Palsy*

Mehta et al described a case of a 36-year-old patient who presented with complaint of numbness, tingling, and weakness of the right side of his face.<sup>23</sup> This patient had fevers, chills, and myalgias for three days prior to his neurologic complaints. The right side of his forehead had no movement, and he was unable to close his right eye.<sup>23</sup> Computed tomography (CT) angiogram of the head showed no abnormalities. He was diagnosed with Bell's palsy, prescribed prednisone and eye lubrication, and discharged to an isolation shelter as the patient was homeless.<sup>23</sup> His COVID-19 swab came back positive, and the patient was transferred further to a COVID-19 isolation shelter.<sup>23</sup>

Goh et al described a case of a patient with facial nerve palsy that developed in a 27-year-old patient on day 6 of his illness with COVID-19, while having been hospitalized for three days.<sup>24</sup> The patient developed left-sided facial weakness that was preceded by left retroauricular pain and dysgeusia.<sup>24</sup> He was started on prednisone and valacyclovir, as well as lopinavir/ritonavir in an attempt to reduce SARS-CoV-2 viral replication.<sup>24</sup> After one week, the patient had no significant change in his facial nerve palsy symptoms.<sup>24</sup>

## Central Nervous System

### *Cerebrovascular Accidents*

From a CNS standpoint, there appears to have been an increase in cases reported of CVA with large vessel occlusion in people younger than 50, with many of these patients testing positive for SARS-CoV-2.<sup>25</sup> Oxley et al found five cases of CVA in patients younger than 50 over a two-week period from March 23–April 7, 2020, with an average National Institutes of Health Stroke Score (NIHSS) of 17, indicating severe infarction. Researchers extracted data from every two-week period over the preceding 12 months and found the baseline rate of CVA in the mentioned age group was 0.73 patients in 14 days.<sup>25</sup> In another study, Li et al performed a single-center, retrospective observational study, which revealed that of the 219 patients with SARS-CoV-2, 10 (4.6%) developed ischemic stroke. Of the patients who tested positive for SARS-CoV-2, they were more likely to have an increased inflammatory response as reflected by the elevated D-dimer (6.9 [0.3-20] vs 0.5 [0.1-20] milligrams per liter [mg/L],  $p < 0.001$ ), and C-reactive protein (51.1 [1.3-127.9] vs 12.1 [0.1-212] mg/L,  $p < 0.05$ ) in these patients compared to patients who did not have SARS-CoV-2.<sup>26</sup>

The Mao et al study revealed a similar finding but took this point further. In their retrospective observational case series, they defined the degree of severity of SARS-CoV-2 infection as severe vs non-severe using the American Thoracic Society guidelines for community-acquired pneumonia.<sup>27</sup> Of the 214 patients who tested positive for SARS-CoV-2, 88 patients had a severe infection and 126 had non-severe infection. Of those 88 patients, five (5.7%) developed cerebrovascular disease vs only one (0.8%) in those with non-severe infection.<sup>2</sup> This suggests that infection with the virus in isolation is not the sole factor for developing cerebrovascular disease. Rather, the illness severity could be playing a role, and likely corresponds to an increased inflammatory state.<sup>2</sup>

### *Cerebral Venous Sinus Thrombosis*

Hughes et al reported of cerebral venous sinus thrombosis, where the patient had presented with headache that progressed to right-sided weakness, numbness, and expressive aphasia with a NIHSS of 10, which was confirmed on CT venogram to be a sigmoid and transverse sinus thrombosis.<sup>28</sup> This patient improved with low-molecular-weight heparin treatment and outpatient apixaban.

### *Acute Myelitis*

There have been cases of acute myelitis, first reported in Wuhan in a patient who was admitted to medical ward for COVID-19, and subsequently developed acute bilateral lower extremity weakness, loss of sensation, hyporeflexia, and urinary incontinence.<sup>29</sup> This patient was positive for SARS-CoV-2, and serologic testing for a plethora of other potential causative agents was negative. Of note, they did find that this patient also had developed CNS involvement, with basal ganglia and periventricular lacunar infarcts.<sup>29</sup>

### *Acute Necrotizing Encephalitis*

There have been reported cases of ANE associated with SARS-CoV-2, which is caused by breakdown of the blood-brain barrier rather than direct viral invasion, providing another route of CNS sequelae, even when the virus does not invade the neuron.<sup>7,9</sup> Radiographic manifestations for ANE include hemorrhagic rim-enhancing lesions within the bilateral thalami, medial temporal lobes, and subinsular regions on magnetic resonance imaging.<sup>7</sup> These patients present with fever, cough, and profound altered mental status. ANE is not the only cause of altered mental status by COVID-19 as there are a growing number of reports and concerns about severe ICU delirium associated with the disease.

### *Delirium*

Beyond the typical causes of ICU delirium, patients with COVID-19 are at even higher risk due to the extreme isolation from human contact.<sup>30</sup> Early reports from Wuhan reported 7.5% of patients with delirium-like findings, but these were likely under-reported since 75% of cases are missed unless the patient is specifically evaluated for delirium.<sup>2,30</sup>

### *Parkinson's Disease*

Patients with underlying neurologic dysfunction such as those with Parkinson's disease (PD) tend to have associated cardiovascular disease and respiratory dysfunction, which puts them at increased risk for developing severe COVID-19. Other comorbidities such as diabetes mellitus and CVA are often found in PD patients, which also places them at higher risk for developing severe COVID-19, given that PD patients on levodopa already have an independently higher risk of CVA.<sup>31</sup> Dyspnea is found in 39% of PD patients, which is secondary to respiratory dysfunction because of respiratory muscle weakness, poor posture, and inadequate respiration excursions.<sup>32</sup> Furthermore, these patients have impaired mastication and swallowing reflexes, leaving them more likely to develop aspiration pneumonia. The combination of these factors along with the neurodegeneration of the medulla's respiratory center, which also can be attacked by SARS-CoV-2, places the PD patient at higher risk for developing more severe pneumonia and ultimately respiratory failure.<sup>33</sup> Also, Parkinsonian hyperpyrexia syndrome, a movement disorder emergency, has been seen in

PD patients with COVID-19 due to the combination of fever and altered dopaminergic medication intake.<sup>34</sup> Although the patients experiencing this phenomenon may recover from COVID-19, some are left with significant disability, while others may not survive.

### **Other Neurologic Sequelae**

The aforementioned pathologies, and those listed in the accompanying table, demonstrate the broad range of neurological sequelae that have been described in the literature. Pathologies that have morbid outcomes, within the setting of potential treatment, were further expanded above. As more is revealed about COVID-19, the table will likely need further expansion of associated complications.

### **Mechanism**

There are numerous theories on the potential causative mechanisms of the neurological sequelae, including the discussed olfactory bulb transmission pathway. Angiotensin-converting enzyme 2 (ACE-2) is a key receptor for cell entry for most coronaviridae, including SARS-CoV-2, and it is present in multiple organ tissues in the body, notably neurons, smooth muscle cells and hepatocytes, with significantly high concentrations in type 2 alveolar cells in the lung.<sup>35</sup> This explains why the virus predominates with respiratory symptoms, especially in the earlier stages. Hematogenous spread to the nervous system has been described, with viral transmission along neuronal synapses in a retrograde fashion.<sup>35</sup> This has been found in other coronaviridae, with viral transmission through the neuron via exocytosis and subsequent binding on ACE-2 receptors, propagating along neuronal channels into the CNS.<sup>35</sup> Neuro-invasion by SARS-CoV-2 is postulated to be at least partially responsible for exacerbating the acute respiratory failure patients with COVID-19 development.<sup>33</sup>

### **LIMITATIONS**

This review has several limitations. Most important is that correlation does not equal causation. As the patients infected with SARS-CoV-2 developed a neurologic complication, the pathophysiology of the virus is unknown. Additionally, the findings described may be attributed to systemic critical illness rather than the etiologic virus specifically. Another limitation is that patients with neurologic symptoms in isolation of cough or fever were not widely tested for SARS-CoV-2 as per CDC guidelines, which have been rapidly evolving. This could in fact lower detection for further cases of neurologic manifestations in the context of a SARS-CoV-2 infection. Lastly, none of the studies reviewed in this article had a control group. There is no evidence in literature yet to identify whether a greater incidence of neurologic manifestations exist with SARS-CoV-2 compared to the inherent risks of developing these neurologic diseases in a native population.

**CONCLUSION**

While the respiratory manifestations caused by the SARS-CoV-2 virus, including significant progression to acute respiratory distress syndrome, are well described, there is a growing body of evidence describing multiorgan involvement, including neurologic sequelae from the virus. While anosmia and dysgeusia have been well documented as diagnostic symptoms from SARS-CoV-2, other peripheral system manifestations such as Guillain-Barré syndrome and ophthalmoparesis have also been seen. A wide spectrum of central nervous system manifestations has been observed from acute necrotizing encephalitis to transverse myelitis. In this review, we update the clinical manifestations of COVID-19 concentrating on the neurological associations that have been described so far, including broad ranges in both central and peripheral nervous systems.

*Address for Correspondence:* Hisham M. Valiuddin, DO, University of Pennsylvania, Department of Emergency Medicine, Ground Floor Ravdin, 3400 Spruce St, Philadelphia, PA 19104. Email: hisham.valiuddin@pennmedicine.upenn.edu.

*Conflicts of Interest:* By the WestJEM article submission agreement, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. No author has professional or financial relationships with any companies that are relevant to this study. There are no conflicts of interest or sources of funding to declare.

*Copyright:* © 2020 Valiuddin et al. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) License. See: <http://creativecommons.org/licenses/by/4.0/>

**Table 1.** List of the largest studies and respective study methodology of recently reported neurological pathologies associated with SARS-CoV-2.

Pathology	Level of evidence	Author
<b>Central</b>		
Large Vessel Occlusion - Cerebrovascular Accident	Retrospective observational study	Mao L. et al <sup>2</sup>
	Case series (5 patients)	Oxley T. et al <sup>25</sup>
	Retrospective observational study	Li Y. et al <sup>26</sup>
	Case series (10 patients)	Berekashvili et al <sup>36</sup>
Transverse Myelitis	Prospective observational study	Lodigiani et al <sup>37</sup>
	Case report	Zhao K. et al <sup>29</sup>
Seizure	Case report	Somani et al <sup>38</sup>
	Retrospective observational study	Galanopolou et al <sup>39</sup>
	Case series (22 patients)	Vollono et al <sup>40</sup>
Myasthenia Gravis	Case report	Anand et al <sup>41</sup>
Acute Necrotizing Encephalopathy	Case series (5 patients)	
Acute Disseminated Encephalomyelitis	Case report	Poyiadji N. et al <sup>7</sup>
Encephalitis/ Meningoencephalitis	Case report	Zhang T. et al <sup>42</sup>
	Case report	Moriguchi T. et al <sup>43</sup>
Corticospinal Tract Signs	Case report	Lorenz et al <sup>44</sup>
Posterior Reversible Encephalopathy Syndrome	Case report	Helms J. et al <sup>45</sup>
	Post mortem study	Kaya et al <sup>46</sup>
Cerebral Venous Sinus Thrombosis	Case report	Coolen et al <sup>47</sup>
<b>Peripheral</b>		
Anosmia and Dysgeusia	Case report	Hughes et al <sup>28</sup>
	Retrospective observational study	Mao L. et al <sup>2</sup>
	Cross sectional study	Lee et al <sup>48</sup>
Motor Peripheral Neuropathy	Cross sectional study	Yan et al <sup>49</sup>
	Case report	Abdelnour et al <sup>50</sup>
Guillain-Barré	Case report	Toscano G. et al <sup>22</sup>
	Case series (5 patients)	Zhao H. et al <sup>29</sup>
	Case report	Virani et al <sup>51</sup>
Ophthalmoparesis	Case report	Dinkin et al <sup>52</sup>
Bell's Palsy	Case Series (2 patients)	
	Case report	Mehta et al. <sup>23</sup>
	Case report	Goh et al. <sup>24</sup>

## REFERENCES

1. Pan L, Mu M, Ren H, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. *Am J Gastroenterol*. 2020;115(5):766-73.
2. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurol*. 2020;77(6):1-9.
3. Netland J, Meyerholz D, Moore S, et al. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. *J. Virol*. 2008;82(15):7264-75.
4. Asadi-Pooya A, Simani L. Central nervous system manifestations of COVID-19: a systematic review. *J Neurol. Sci*. 2020;116832.
5. Platt M, Agalliu D. et al. Hello from the other side: how autoantibodies circumvent the blood-brain barrier in autoimmune encephalitis. *Front Immunol*. 2017;8:442.
6. Platt M, Bolding K, Wayne C, et al. Th17 lymphocytes drive vascular and neuronal deficits in a mouse model of postinfectious autoimmune encephalitis. *Proc Natl Acad Sci U S A*. 2020;117(12):6708–16.
7. Poyiadji N, Shahin G, Noujaim D, et al. COVID-19–associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. *Radiology*. 2020;296(2):119-20.
8. Oudkerk M, Büller H, Kuijpers D, et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands. *Radiology*. 2020;201629
9. Mehta P, McAuley D, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-4
10. Van Doremalen N, Bushmaker T, Morris D, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. *N Engl J Med*. 2020;382(16):1564-7.
11. Wang D, Hu B, Hu C. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. *JAMA*. 2020;323(11):1061-9.
12. Benezit F, Le Turnier P, Declerck C, et al. Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. *Lancet*. 2020;20(9):1014-5.
13. Suzuki M, Saito K, Min W, et al. Identification of viruses in patients with postviral olfactory dysfunction. *Laryngoscope*. 2007;117(2):272-7.
14. Seiden A. Postviral olfactory loss. *Otolaryngol Clin North Am*. 2004;37(6):1159-66.
15. Douek E, Bannister L, Dodson H. Olfaction and its disorders: recent advances in the pathology of olfaction. *J R Soc Med*. 1975;467-70
16. Jafek B, Hartman D, Eller P, et al. Postviral olfactory dysfunction. *Am J Rhinol*. 1990;4(3):91-100.
17. Yamagishi M, Fujiwara M, Nakamura H. Olfactory mucosal findings and clinical course in patients with olfactory disorders following upper respiratory viral infection. *Rhinology*. 1994;32(3):113.
18. Yamagishi M, Hasegawa S, Nakano, Y. Examination and classification of human olfactory mucosa in patients with clinical olfactory disturbances. *Arch Otorhinolaryngol*. 1988;245(5):316-20.
19. Yamagishi M, Nakano Y. A re-evaluation of the classification of olfactory epithelia in patients with olfactory disorders. *Eur Arch Otorhinolaryngol*. 1992;249(7):393-9.
20. Vaira L, Salzano G, Deiana G. et al. Anosmia and ageusia: common findings in COVID-19 patients. *The Laryngoscope*. 2020;130(7):1787.
21. Sedaghat Z and Karimi N. Guillain Barré syndrome associated with COVID-19 infection: a case report. *J Clin Neurosci*. 2020;76:233-5.
22. Toscano G, Palmerini F, Ravaglia S, et al. Guillain–Barré syndrome associated with SARS-CoV-2. *N Engl J Med*. 2020;382(26):2574-6.
23. Mehta S, Mackinnon D, Gupta S. Severe acute respiratory syndrome coronavirus 2 as an atypical cause of Bell’s palsy in a patient experiencing homelessness. *CJEM*. 2020:1-3.
24. Goh Y, Beh D, Makmur A, et al. Pearls & Oy-sters: Facial nerve palsy as a neurological manifestation of Covid-19 infection. *Neurology*. 2020;95(8):364-7.
25. Oxley T, Mocco J, Majidi S, et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. *N Engl J Med* 2020;382(20):60.
26. Li Y, Wang M, Zhou Y, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. *Stroke Vasc Neurol*. 2020. In Press.
27. Metlay J, Waterer G, Long A, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med*. 2019;200(7):45-67.
28. Hughes C, Nichols T, Pike M, et al. Cerebral venous sinus thrombosis as a presentation of COVID-19. *Eur J Intern Med*. 2020;7(5):1691.
29. Zhao K, Huang J, Dai D, et al. Acute myelitis after SARS-CoV-2 infection: a case report. *medRxiv*. 2020. In Press.
30. Kotfis K, Roberson S, Wilson J, et al. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. *Crit Care*. 2020;24(1):176.
31. Garcia-Gracia C, Khan T, Reyes D, et al. The prevalence of stroke in Parkinson’s disease is high: a risk factor assessment. *Neurology*. 2013;80(7).
32. Bhidayasiri R, Virameteekul S, Kim J, et al. COVID-19: an early review of its global impact and considerations for Parkinson’s disease patient care. *J Mov Disord*. 2020;13(2):105-14.
33. Li Y, Bai W, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients. *J Med Virol*. 2020;92(6):552-5.
34. Rajan S, Kaas B, Moukheiber E. Movement disorders emergencies. *Semin Neurol*. 2019;39(1):125–36.
35. Iroegbu J, Ifenatuoha C, Ijomone O. Potential neurological impact of coronaviruses: implications for the novel SARS-CoV-2. *Neurol Sci*. 2020;41(6):1329-37.
36. Dmytriw A, Vulkanov V, Agarwal S, et al. Etiologic subtypes of ischemic stroke in SARS-COV-2 virus patients. *medRxiv*. 2020. In Press.
37. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an

- academic hospital in Milan, Italy. *Thromb Res.* 2020;191:9-14.
38. Somani S, Pati S, Gaston T, et al. De novo status epilepticus in patients with COVID-19. *Ann Clin Transl Neurol.* 2020;7(7):1240-4.
  39. Galanopoulou A, Ferastraoar V, Correa D, et al. EEG findings in acutely ill patients investigated for SARS-CoV2/COVID-19: a small case series preliminary report. *Epilepsia Open.* 2020;5(2):314-24.
  40. Vollono C, Rollo E, Romozzi M, et al. Focal status epilepticus as unique clinical feature of COVID-19: a case report. *Seizure.* 2020;78:109-112.
  41. Anand P, Slama M, Kaku M, et al. COVID-19 in patients with myasthenia gravis. *Muscle Nerve.* 2020;62(2):254-8.
  42. Zhang T, Rodricks M, Hirsh E. COVID-19-associated acute disseminated encephalomyelitis: a case report. *medRxiv.* 2020. In Press.
  43. Moriguchi T, Harii N, Goto J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int J Infect Dis.* 2020;94:55-8.
  44. Lorenz N, Treptow A, Schmidt S, et al. Neonatal early-onset infection with SARS-CoV-2 in a newborn presenting with encephalitic symptoms. *Pediatr Infect Dis J.* 2020;39(8):212.
  45. Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. *N Engl J Med.* 2020;382(23): 2268-70.
  46. Kaya Y, Kara S, Akinci C, et al. Transient cortical blindness in COVID-19 pneumonia; a PRES-like syndrome: a case report. *J Neurol Sci.* 2020;413:116858.
  47. Coolen T, Lolli V, Sadeghi N, et al. Early postmortem brain MRI findings in COVID-19 non-survivors. *Neurology.* 2020;10:1212.
  48. Lee Y, Min P, Lee S, et al. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. *J Korean Med Sci.* 2020;35(18):174.
  49. Yan C, Faraji F, Prajapati D, et al. Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms. *Int Forum Allergy Rhinol.* 2020;10(7):806-13.
  50. Abdelnour L, Abdalla M, Babiker S, et al. COVID 19 infection presenting as motor peripheral neuropathy. *J Formos Med Assoc.* 2020;119(6):1119-20.
  51. Virani A, Rabold E, Hanson T, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection. *IDCases.* 2020;20: e00771.
  52. Dinkin M, Gao V, Kahan J, et al. COVID-19 presenting with ophthalmoparesis from cranial nerve palsy. *Neurology.* 2020;95(5):221-3.